BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2323 related articles for article (PubMed ID: 32835632)

  • 1.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
    Maurya SK; Maurya AK; Mishra N; Siddique HR
    J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an
    Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK
    J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.
    Aldahham BJM; Al-Khafaji K; Saleh MY; Abdelhakem AM; Alanazi AM; Islam MA
    J Biomol Struct Dyn; 2022 Jun; 40(9):3899-3906. PubMed ID: 33252031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.
    Chidambaram SK; Ali D; Alarifi S; Radhakrishnan S; Akbar I
    J Infect Public Health; 2020 Nov; 13(11):1671-1677. PubMed ID: 33008777
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
    Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
    Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
    J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual Screening of
    Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
    Selvaraj C; Dinesh DC; Panwar U; Abhirami R; Boura E; Singh SK
    J Biomol Struct Dyn; 2021 Aug; 39(13):4582-4593. PubMed ID: 32567979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 117.